CSF3 and acute myeloid leukemia: In the current study, we designed a regimen that included chidamide, demethylating drugs (azacitidine), cytarabine, aclacinomycin, G‐CSF, and venetoclax (CDCAG‐VEN) for the treatment of patients with R/R AML.